News and developments
Company developments, research and events.
The First Seat on the Left, Front Row
Tonight, the 2026 Nobel Prize in Physiology or Medicine was announced in Stockholm. For those of us who have spent decades working on GLP-1, the announcement inevitably brings a certain feeling. But the first image that came to my mind was not Stockholm. It was Milan, just a few days ago—and a familiar seat in the front row.
Innogen’s efsubaglutide alfa program wins first prize from the Chinese Pharmaceutical Association
The association’s Science and Technology Award recognizes the development and application of efsubaglutide alfa, following Innogen’s work from original molecular research to an approved medicine.
Two contract manufacturing sites receive ANVISA GMP certification
Two contract sites manufacturing efsubaglutide alfa in China received GMP certificates from Brazil’s ANVISA. Both sites are owned and operated by an independent third party. Certification concerns manufacturing and quality systems; authorization to market the medicine in Brazil is a separate process.
First participant enrolled in the adolescent obesity Phase Ib study of efsubaglutide alfa
Innogen is extending efsubaglutide alfa’s clinical development to adolescents with obesity. The Phase Ib trial evaluates safety, tolerability, pharmacokinetics and pharmacodynamics.
Qinghua Wang discusses GLP-1 development and its outlook at CPIC 2026
At the first China Pharmaceutical Innovation Conference, Wang used efsubaglutide alfa to discuss the full path from original discovery and molecular design to clinical development and commercialization.
Qinghua Wang discusses the development of a China-originated GLP-1 medicine at Hunan conference
The report traced more than two decades of GLP-1 research, connecting long-acting molecular design, manufacturability and clinical translation.